CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon
      Google Scholar   
Citation:
Ann Oncol vol 25 (suppl 4) 5010
Meeting Instance:
ESMO 2014
Year:
2014
Type:
Abstract
Sub type:
Oral
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
2637  
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                               
Networks:
 
Study
Alliance-80405
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
Keywords: